Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Metabolomic testing of a putative MDH inhibitor (targeted)

ABSTRACT: HL-60 cells will be treated for 15hr with a putative MDH inhibitor or vehicle (n=5 per group)

ORGANISM(S): Human Homo Sapiens

TISSUE(S): Leukemia Cells

DISEASE(S): Cancer

SUBMITTER: David Wald

PROVIDER: ST000474 | MetabolomicsWorkbench | Wed Aug 31 00:00:00 BST 2016

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

Metabolomic testing of a putative MDH inhibitor (global)

Project description:HL-60 cells will be treated for 15hr with a putative MDH inhibitor or vehicle (n=5 per group)

2016-09-12 | ST000475 | MetabolomicsWorkbench

Transcriptomic analysis of the effects of mTOR inhibitor everolimus, CDK8/19 inhibitor SNX631 and their combination in MDA-MB-468 xenografts

Project description:RNA-Seq analysis was carried out to investigate the transcriptomic changes associated with the development of in vivo everolimus resistance and the effects of CDK8/19 inhibition on the development of resistance in MDA-MB-468 TNBC xenografts. In one study (short-term), tumor samples were collected after 30-40 days of treatment with vehicle or everolimus, when the tumor growth was still suppressed by the mTOR inhibitor. In another study (long-term), tumor samples were collected after 60-153 days of treatment with vehicle, everolimus, CDK8/19 inhibitor SNX631 or their combination, when tumors treated with everolimus but not with the drug combination developed resistance.

2024-10-31 | GSE271325 | GEO

Effect of 8-oxoguanine DNA glycosylase 1 (OGG1) inhibitor on pro-inflammatory gene expression.

Project description:Balbc J mouse received vehicle (solvent) or OGG1 inhibitor 1 h prior to treatment via intraperitoneal route. Tumor necrosis factor alpha (TNFa, 20 ng per ml) was installed into lungs via intranasal route in 60 microliters of solvent). One hour after TNFa challenge mice were sacrificed, lungs were removed and RNAs were isolated from individual lungs (n=6) After reverse transcription cDNAs were pooled and changes in gene expression was determined by using SABiosciences Mouse Inflammatory Cytokines & Receptors PCR Array (PAMM-011Z)

2018-07-10 | GSE116809 | GEO

Quantitative proteomic analysis of hippocampal tissues from mice treated with a CK1δ/ε inhibitor

Project description:Hippocampal tissues from 3xTg-AD mice treated with a CK1δ/ε inhibitor or vehicle, and non-transgenic mice treated with vehicle, were harvested and processed for proteomic analysis using label-free quantification.

2019-07-30 | PXD012281 | Pride

Proteomic and phosphoproteomic profiling of ARPE19 cells and Abca4-/-Rdh8-/- mice exposed to stress

Project description:To obtain an unbiased, thorough understanding of the biological pathways implicated in atRAL-induced cytotoxicity and PDE inhibitor-mediated cytoprotection, we performed a mass spectrometry-based quantitative proteomic analysis of ARPE19 cells, using stable-isotope labeling of amino acids in cell culture (SILAC). We identified differentially expressed proteins in ARPE19 cells exposed to stress (60 μM atRAL or 5 mM H2O2) in the absence or presence of PDE inhibitor (10 μM BAY 60-7550, rolipram, or BC11-38), relative to vehicle-treated controls. We also performed combined label-free mass spectrometry-based quantitative proteomic and phosphoproteomic analyses of retinas from the Abca4-/-Rdh8-/- double-knockout (dKO) light-sensitive mouse model of photoreceptor degeneration. First, we identified differentially expressed proteins in retinas exposed to bright-light stress (10,000 lux for 30 min) relative to unstressed controls. Next, we identified differentially expressed proteins in PDE inhibitor-treated mice (2 mg/kg intraperitoneal BAY 60-7550, rolipram, or BC11-38) exposed to stress relative to DMSO vehicle-treated controls. Altogether, these analyses provided insights into the proteomic and phosphoproteomic changes induced by stress and modulated by PDE-inhibitor therapy.

2024-01-26 | PXD035841 | Pride

Mouse brain microarray, Chronic HDAC inhibitor treatment

Project description:Here, we examined mouse brain trancriptional changes 1 hour after the 10th daily i.p. treament with one of the four following treaments: i) vehicle control (45% saline, 45% PEG-400 and 10% DMSO administered at 7.5mL/kg), ii) Cpd-60, 45mg/kg , administered at 7.5mL/kg or iii) SAHA, 25mg/kg, administered at 5mL/kg) or iv) CI-994, 10mg/kg, administered at 5mL/kg. Cpd-60 is a benzamide HDAC inhibitor with selectivity for class I HDAC subtypes HDAC1 and HDAC2; CI-994 is a benzamide inhibitor with selectivity for HDACs1,2 and 3; SAHA is a hydroxamic acid HDAC inhibitor with selectivity for class I HDAC subtypes 1,2, and 3 and the class II HDAC subtype HDAC 6. We examined transcript differences using the Illumnia WG-6 2.0 whole genome expression array and profiled 3 specific brain regions (prefrontal cortex, nucleus accumbens, hippocampus) from each of 36 mice (n=6 mice / treatment group) . For application to array chips, we pooled two biological replicates from like treatment and brain region-groups such that 36 samples were applied in total: 4 treatment groups x 3 brain regions per treament group x 3 pools of two samples each for each treatment/brain region.

2013-05-29 | GSE47452 | GEO

Effect of ROCK Inhibitor on myeloid cells during GvHD

Project description:GvHD mice (allo transplant) and treated mice with ROCK Inhibitor 8mg /kg or PBS (vehicle)

2023-12-04 | GSE229043 | GEO

RNAseq of liver harvested from CDAHFD mice treated for 8 weeks with either the MGAT2 inhibitor compound BMS-963272 or vehicle

Project description:This experiment consists of RNAseq of liver harvested from CDAHFD mice treated for 8 weeks with either the MGAT2 inhibitor compound BMS-963272 (N = 10) or with vehicle (N = 10).

| EGAS00001006583 | EGA

The effect of HDAC inhibitor, 4b, on skeletal muscle gene expression

Project description:To assess the effects of histone deacetylase (HDAC) inhibitor, HDACi 4b, treatment on muscle function on a molecular level, we performed microarray analysis on skeletal muscle (gastrocnemius) samples from wt and N17182Q mice treated with the HDAC inhibitor 4b for 3 months (50 mg/kg; s.c. injection 3x weekly; n=4 per group). The transcriptome pattern in N17182Q mice compared to wt controls consisted of deficits in the expression of genes related to mitochondrial function and oxidative metabolism. In addition, we noted that numerous genes associated with basal contractile function were altered in HD N17182Q mice. These include genes related to the muscle contractile complex, Tnnt3 and Myh8, as well as several additional myosin genes: myosin heavy chain genes, Myh10 and Myh4, and myosin light chain genes, Myl1, Mylc2 and Mylk. These findings implicate deficits in the underlying contractile function in skeletal muscle from HD mice. Further, we found robust effects of 4b treatment on the expression of genes in skeletal muscle, with 556 genes showing significantly altered expression, at p<0.005, in 4b-treated N17182Q muscle compared to vehicle-treated control mice. n=4 vehicle-treated WT mice, n=5 HDACi 4b-treated WT mice, n=4 vehicle-treated N17182Q transgenic mice, and n=3 HDACi 4b-treated N17182Q transgenic mice.

2014-11-01 | E-GEOD-56963 | biostudies-arrayexpress

Expression Profiling of Mixed Lineage Leukemia Cells Treated with a Potent Small-Molecule DOT1L Inhibitor

Project description:Cell lines bearing MLL translocations (MV4-11 and MOLM-13) were treated with a potent, selective inhibitor of the DOT1L histone methyl transferase. Treatment of MLL-rearranged cell lines with the DOT1L inhibitor selectively inhibits H3K79 methylation and blocks expression of leukemogenic genes. Here we provide expression profiling data of cells treated with DOT1L inhibitor or vehicle control. MV4-11 cells were treated with 3 uM EPZ004777 (DOT1L inhibitor) or vehicle control (0.1% DMSO) for 2, 4 and 6 days. MOLM-13 cells were treated with 3 uM EPZ004777 (DOT1L inhibitor) or vehicle control (0.1% DMSO) for 6 days. For each unique conditon, 3 biological replicates were generated for expression profiling.

2011-07-11 | E-GEOD-29828 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data